Today at the @ASH_hematology Annual Meeting & Exposition, we will share 2-year outcomes and updates on our Phase 1 study of GDA-201 in combination with rituximab in patients with non-Hodgkin lymphoma.
Learn more here: https://t.co/CqDKW33SIU
#ASH21 https://t.co/pgBgXQW97J